Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 362

Similar articles for PubMed (Select 17084785)

1.

Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia.

Krupitsky EM, Zvartau EE, Masalov DV, Tsoy MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE.

J Subst Abuse Treat. 2006 Dec;31(4):319-28. Epub 2006 Jul 24.

PMID:
17084785
2.

Naltrexone for heroin dependence treatment in St. Petersburg, Russia.

Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY, Didenko TY, Romanova TN, Ivanova EB, Bespalov AY, Verbitskaya EV, Neznanov NG, Grinenko AY, O'Brien CP, Woody GE.

J Subst Abuse Treat. 2004 Jun;26(4):285-94.

PMID:
15182893
3.

[Naltrexone and fluoxetine for maintenance of remission in patients with heroin addiction: a double-blind randomized placebo-controlled trial].

Krupitskiĭ EM, Zvartau EE, Tsoĭ-Podosenin MV, Masalov DV, Burakov AM, Egorova VIu, Didenko TIu, Romanova TN, Ivanova EB, Bespalov AIu, Verbitskaia EV, Neznanov NG, Grineneko AIa, O'Brien C, Woody D.

Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(5 Pt 2):44-54. Russian.

PMID:
21322147
4.

Hostility in heroin abusers subtypes: fluoxetine and naltrexone treatment.

Gerra G, Fertonani G, Zaimovic A, Rota-Graziosi I, Avanzini P, Caccavari R, Delsignore R, Lucchini A.

Prog Neuropsychopharmacol Biol Psychiatry. 1995 Dec;19(8):1225-37.

PMID:
8868205
5.

Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence.

Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V, Tsoy-Podosenin M, Bushara N, Burakov A, Masalov D, Romanova T, Tyurina A, Palatkin V, Slavina T, Pecoraro A, Woody GE.

Arch Gen Psychiatry. 2012 Sep;69(9):973-81. doi: 10.1001/archgenpsychiatry.2012.1a.

6.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
7.

[Pharmacotherapy in heroin addiction: pharmacological approaches to remission stabilization and recurrence prevention].

Grinenko AIa, Krupitskiĭ EM, Zvartau EE.

Vestn Ross Akad Med Nauk. 2003;(10):54-6. Russian.

PMID:
14598513
8.

A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts.

Landabaso MA, Iraurgi I, Jiménez-Lerma JM, Sanz J, Fernádez de Corres B, Araluce K, Calle R, Gutiérrez-Fraile M.

Addiction. 1998 May;93(5):739-44.

PMID:
9692272
9.

Naltrexone shortened opioid detoxification with buprenorphine.

Umbricht A, Montoya ID, Hoover DR, Demuth KL, Chiang CT, Preston KL.

Drug Alcohol Depend. 1999 Oct 1;56(3):181-90.

PMID:
10529020
10.

Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial.

Jayaram-Lindström N, Hammarberg A, Beck O, Franck J.

Am J Psychiatry. 2008 Nov;165(11):1442-8. doi: 10.1176/appi.ajp.2008.08020304. Epub 2008 Sep 2.

PMID:
18765480
11.

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

Adi Y, Juarez-Garcia A, Wang D, Jowett S, Frew E, Day E, Bayliss S, Roberts T, Burls A.

Health Technol Assess. 2007 Feb;11(6):iii-iv, 1-85. Review.

12.

Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial.

Schottenfeld RS, Chawarski MC, Mazlan M.

Lancet. 2008 Jun 28;371(9631):2192-200. doi: 10.1016/S0140-6736(08)60954-X.

13.

The efficacy of naltrexone in preventing reabuse of heroin after detoxification.

Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y.

Biol Psychiatry. 1994 Jun 15;35(12):935-45.

PMID:
8080893
14.

Overcoming opioid blockade from depot naltrexone (Prodetoxon).

Kruptisky EM, Burakov AM, Tsoy MV, Egorova VY, Slavina TY, Grinenko AY, Zvartau EE, Woody GE.

Addiction. 2007 Jul;102(7):1164-5. Erratum in: Addiction. 2007 Aug;102(8):1334.

PMID:
17498182
15.

A randomized control trial of group counseling in a naltrexone treatment program.

Tucker T, Ritter A, Maher C, Jackson H.

J Subst Abuse Treat. 2004 Dec;27(4):277-88.

PMID:
15610829
16.

Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder.

Martenyi F, Brown EB, Zhang H, Koke SC, Prakash A.

Br J Psychiatry. 2002 Oct;181:315-20.

17.

A pilot study of naltrexone-accelerated detoxification in opioid dependence.

Bell JR, Young MR, Masterman SC, Morris A, Mattick RP, Bammer G.

Med J Aust. 1999 Jul 5;171(1):26-30.

PMID:
10451668
19.

Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial.

Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, Kristensen Ø, Waal H.

Br J Psychiatry. 2009 Jun;194(6):541-6. doi: 10.1192/bjp.bp.108.055319.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk